Search

Search Constraints

You searched for: Author/Creator Reiser, Marcel

Search Results

1. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3, 717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). (February 2021)

2. Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3, 717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174–184]. (July 2021)

3. Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Issue 5 (3rd May 2016)

4. FOLFIRINOX or gemcitabine/nab‐paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision‐making in real‐world. Issue 3 (22nd September 2022)

5. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long‐term data of the SIGNS study. (21st June 2017)

6. Myelodysplastic syndromes (MDS) in regular care in Germany – the oldest patients come to the fore. Issue 5 (4th May 2018)

7. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. (February 2021)

8. Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice. (22nd March 2018)

10. Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel. (March 2023)